Children with psoriasis and COVID-19: factors associated with an unfavourable COVID-19 course, and the impact of infection on disease progression (Chi-PsoCov registry)

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Tyck till om SwePub Sök här!

Sökning: WFRF:(Sonkoly E) > Children with psori...

1 av 90
Föregående post
Nästa post
Till träfflistan

Children with psoriasis and COVID-19 : factors associated with an unfavourable COVID-19 course, and the impact of infection on disease progression (Chi-PsoCov registry)

Zitouni, J. (författare): Hop Victor Dupouy, Dept Dermatol, Argenteuil, France.

Bursztejn, A-C (författare): Ctr Hosp Univ Nancy, Dept Dermatol, Hop Brabois, Vandoeuvre Les Nancy, France.

Fortina, A. Belloni (författare): Univ Padua, Dept Med DIMED, Pediat Dermatol Unit, Padua, Italy.

visa fler...

Beauchet, A. (författare): Hop Ambroise Pare, Dept Publ Hlth, Boulogne, France.

Di Lernia, V (författare): Azienda USL IRCCS Reggio Emilia, Dermatol Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy.

Lesiak, A. (författare): Med Univ Lodz, Dept Dermatol Peadiat Dermatol & Oncol, Lodz, Poland.

Thomas, J. (författare): JT Skin Care Ctr, Chennai, Tamil Nadu, India.

Topkarci, Z. (författare): Dr Sadi Konuk Training & Res Hosp, Dept Dermatol, Istanbul, Turkey.

Murashkin, N. (författare): Minist Hlth Russian Federat, Sci Ctr Childrens Hlth, Fed State Autonomous Inst, Dept Dermatol, Moscow, Russia.

Brzezinski, P. (författare): Voivodship Specialist Hosp Slupsk, Dept Dermatol, Ustka, Poland.

Torres, T. (författare): Ctr Hosp Univ Porto, Dept Dermatol, Porto, Portugal.

Chiriac, A. (författare): Romanian Acad, Nicolina Med Ctr, P Poni Inst Macromol Chem, Dept Dermatol, Iasi, Romania.

Luca, C. (författare): Gr T Popa Univ Med, Sf Parascheva Clin Hosp, Infect Dis Dept, Iasi, Romania.

McPherson, T. (författare): Oxford Univ Hosp NHS Trust, Dept Dermatol, Oxford, England.

Akinde, M. (författare): Guys & St Thomas NHS Fdn Trust, St Johns Inst Dermatol, Dept Paediat Dermatol, London, England.

Maruani, A. (författare): Univ Tours & Nantes, Dept Dermatol, Unit Pediat Dermatol, INSERM 1246 SPHERE CHRU Tours, Tours, France.

Epishev, R. (författare): Minist Hlth Russian Federat, Sci Ctr Childrens Hlth, Fed State Autonomous Inst, Dept Dermatol, Moscow, Russia.

de la Cruz, H. Vidaurri (författare): Hosp Gen Mexico Dr Eduardo Liceaga, Serv Dermatol Pediat, Secretaria Salud, Ciudad De Mexico, Mexico.

Luna, P. C. (författare): Hosp Aleman, Dept Dermatol, Buenos Aires, DF, Argentina.

de la Breteque, M. Amy (författare): Hop Victor Dupouy, Dept Dermatol, Argenteuil, France.

Lasek, A. (författare): Univ Catholique Lille, Dept Dermatol, Hop St Vincent Paul, Lille, France.

Bourrat, E. (författare): Hop Robert Debre, AP HP, Dept Dermatol, Paris, France.

Bachelerie, M. (författare): Ctr Hosp Univ, Dept Dermatol, Clermont Ferrand, France.

Mallet, S. (författare): Hop La Timone, AP HM, Dept Dermatol, Marseille, France.

Steff, M. (författare): Ctr Hosp Intercommunal Robert Ballanger, Dept Dermatol, Aulnay Sous Bois, France.

Bellissen, A. (författare): Ctr Hosp Edmond Garcin, Dept Dermatol, Aubagne, France.

Neri, I (författare): IRCSS Azienda Osped Univ Bologna, Dept Dermatol, Bologna, Italy.

Zafiriou, E. (författare): Univ Thessaly, Fac Med, Sch Hlth Sci, Dept Dermatol, Larisa, Greece.

van den Reek, J. M. P. A. (författare): Radboud Univ Nijmegen, Dept Dermatol, Med Ctr, Nijmegen, Netherlands.

Sonkoly, Enikö (författare): Karolinska Institutet,Uppsala universitet,Dermatologi och venereologi,Karolinska Inst, Dept Med Solna, Dermatol & Venereol Div, Stockholm, Sweden.;Karolinska Inst, Ctr Mol Med CMM, Stockholm, Sweden.

Mahil, S. K. (författare): Guys & St Thomas NHS Fdn Trust, St Johns Inst Dermatol, London, England.;Kings Coll London, London, England.

Smith, C. H. (författare): Guys & St Thomas NHS Fdn Trust, St Johns Inst Dermatol, London, England.;Kings Coll London, London, England.

Flohr, C. (författare): Guys & St Thomas NHS Fdn Trust, St Johns Inst Dermatol, Dept Paediat Dermatol, London, England.

Bachelez, H. (författare): Hop St Louis, AP HP, Dept Dermatol, Paris, France.;Univ Paris, Imagine Inst, INSERM U1163, Lab Genet Skin Dis, Paris, France.

Mahe, E. (författare): Hop Victor Dupouy, Dept Dermatol, Argenteuil, France.

visa färre...

Hop Victor Dupouy, Dept Dermatol, Argenteuil, France Ctr Hosp Univ Nancy, Dept Dermatol, Hop Brabois, Vandoeuvre Les Nancy, France. (creator_code:org_t)

2022-07-06
2022
Engelska.
Ingår i: Journal of the European Academy of Dermatology and Venereology. - : John Wiley & Sons. - 0926-9959 .- 1468-3083. ; 36:11, s. 2076-2086

Relaterad länk:: https://urn.kb.se/re...; visa fler...; https://doi.org/10.1...; http://kipublication...; visa färre...

Tidskriftsartikel (refereegranskat)

Abstract Ämnesord

Stäng

Background The COVID-19 pandemic has raised questions regarding the management of chronic skin diseases, especially in patients on systemic treatments. Data concerning the use of biologics in adults with psoriasis are reassuring, but data specific to children are missing. Moreover, COVID-19 could impact the course of psoriasis in children. Objectives The aim of this study was therefore to assess the impact of COVID-19 on the psoriasis of children, and the severity of the infection in relation to systemic treatments. Methods We set up an international registry of paediatric psoriasis patients. Children were included if they were under 18 years of age, had a history of psoriasis, or developed it within 1 month of COVID-19 and had COVID-19 with or without symptoms. Results One hundred and twenty episodes of COVID-19 in 117 children (mean age: 12.4 years) were reported. The main clinical form of psoriasis was plaque type (69.4%). Most children were without systemic treatment (54.2%); 33 (28.3%) were on biologic therapies, and 24 (20%) on non-biologic systemic drugs. COVID-19 was confirmed in 106 children (88.3%) and 3 children had two COVID-19 infections each. COVID-19 was symptomatic for 75 children (62.5%) with a mean duration of 6.5 days, significantly longer for children on non-biologic systemic treatments (P = 0.02) and without systemic treatment (P = 0.006) when compared with children on biologics. The six children who required hospitalization were more frequently under non-biologic systemic treatment when compared with the other children (P = 0.01), and particularly under methotrexate (P = 0.03). After COVID-19, the psoriasis worsened in 17 cases (15.2%). Nine children (8%) developed a psoriasis in the month following COVID-19, mainly a guttate form (P = 0.01). Discussion Biologics appear to be safe with no increased risk of severe form of COVID-19 in children with psoriasis. COVID-19 was responsible for the development of psoriasis or the worsening of a known psoriasis for some children.

Hitta via bibliotek

Journal of the European Academy of Dermatology and Venereology (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

1 av 90
Föregående post
Nästa post
Till träfflistan

Hitta mer i SwePub

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Dermatologi och ...

Artiklar i publikationen: Journal of the E ...

Av lärosätet: Uppsala universitet; Karolinska Institutet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se

Children with psoriasis and COVID-19 : factors associated with an unfavourable COVID-19 course, and the impact of infection on disease progression (Chi-PsoCov registry)

Ämnesord

Publikations- och innehållstyp

Hitta via bibliotek

Till lärosätets databas

Hitta mer i SwePub

Sök utanför SwePub